Aristotle University Of Thessaloniki (AUTH)
Ανακάλυψη νέων φαρμακολογικών στόχων για την Πλάγια Αμυοτροφική Σκλήρυνση (ALS)
Abstract
dc:descriptionAmyotrophic Lateral Sclerosis (ALS) is a rare degenerative disease of the motor neurons, affecting about 2 in every 100,000 people. It is mainly characterized by cramps and muscle weakness in the upper and/or lower limbs, leading to paralysis and usually premature death within an average of 3 to 5 years from symptom onset. There are two types of ALS: sporadic, which occurs randomly without any family history, and familial, which is inherited. The causes of the disease are not fully understood, but genetic and environmental factors play a role. More than 30 genes have been found to cause familial ALS, leading to protein deposits consisting of different proteins such as SOD1, TDP-43, and FUS. The aim of this thesis was to investigate the role of proteolysis, likely controlled by KLK6, and the role of NRF2, the main transcription factor associated with antioxidant action, in ALS. Initially, the study showed that it is necessary to distinguish the patients with ALS based on their genetic profile for an effective pharmacotherapeutic approach in a chemogenomic-like way. The study then focused on the SOD1-ALS category, which is characterized by increased oxidative stress, and tested the efficacy of administering Dimethyl Fumarate (DMF) to Tg-SOD1G93A mice. DMF is an approved drug for psoriasis and relapsing remitting multiple sclerosis that is considered to activate the NRF2. The results showed that female mice showed slight improvement in symptoms and a delayed onset of the disease, without an increase in the survival time. The study also demonstrated that KLK6 could proteolyze monomeric SOD1 and SOD1G93A derived from the lumbar spinal cord protein extract. Additionally, it was found that female Tg-SOD1G93AKlk6+/- mice presented milder symptoms compared to female mice with Tg-SOD1G93A genotype. Finally, it was found that DMF administration to Tg-SOD1G93A mice increased Klk6 expression levels, while SH-SY5Y cell stimulation with KLK6 activated the NRF2 pathway, possibly indicating a relationship between NRF2 and KLK6. These results suggest that DMF could be used to treat ALS patients characterized by mutations in the SOD1 gene, especially in female individuals. In addition, KLK6 may be involved in the progression of SOD1-related disease through multiple mechanisms involving activation of the Nrf2 pathway and proteolysis of SOD1. Notably, deletion of one Klk6 allele in Tg-SOD1G93A mice resulted in only slight improvement in phenotype, particularly in female mice, indicating the involvement of extra unknown pathways dependent on KLK6 in SOD1-ALS. Finally, the study showed that the SOD1G93A protein could be immobilized in calcium pyrophosphate particles and thus used as an antigen in future vaccinations to treat SOD1-ALS patients.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Angelis, Georgios
- Αγγελής, Γεώργιος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56802